PCSS-MAUD Webinar: Injecting Hope - GLP-1 Receptor Agonists for the Treatment of Alcohol Use Disorder-Slides

Slides

Pdf Summary

This webinar reviewed the emerging role of GLP-1 receptor agonists, especially semaglutide and tirzepatide, as potential treatments for alcohol use disorder (AUD). It began by noting how common unhealthy alcohol use and AUD remain in the U.S., while existing medications for AUD are underused. The presenter explained GLP-1 biology, including how these drugs act on brain reward pathways involved in appetite, satiety, craving, and reinforcement.<br /><br />Preclinical animal studies consistently show that GLP-1 signaling reduces alcohol intake and alcohol reward. Human evidence is still developing, but observational studies and registry data suggest lower alcohol-related events and fewer AUD hospitalizations among people using GLP-1 drugs, particularly semaglutide. Early randomized trials were mixed: exenatide did not reduce drinking overall, though it reduced cue-reactivity and may have helped obese participants. More recent semaglutide trials reported more encouraging results, including reduced alcohol self-administration, fewer heavy drinking days, and lower cravings.<br /><br />The webinar also discussed ongoing and planned clinical trials of semaglutide, tirzepatide, and related agents across AUD, opioid use disorder, smoking, and binge-eating disorder. The speaker emphasized that GLP-1s are promising but not yet established AUD treatments, and that standard FDA-approved AUD medications should still be optimized first.<br /><br />Potential concerns were reviewed, including gastrointestinal side effects, pancreatitis, gallstones, possible interactions with oral medications, weight regain after stopping therapy, stigma, and the need to monitor for disordered eating. Overall psychiatric safety appears reassuring, with meta-analyses showing no increased risk of depression or suicidality.<br /><br />Conclusion: GLP-1 receptor agonists may represent a novel, biologically plausible treatment avenue for AUD, but stronger randomized evidence is still needed before routine recommendation.

Keywords

GLP-1 receptor agonists

semaglutide

tirzepatide

alcohol use disorder

AUD

brain reward pathways

alcohol craving

randomized trials

clinical trials

psychiatric safety